Ask AI
ProCE Banner Activity

Schizophrenia Care: From Emerging Evidence to Everyday Care

Slideset

Schizophrenia care continues to face persistent gaps in negative symptoms, cognitive impairment, tolerability, adherence, and long-term functional recovery. This slideset reviews how muscarinic M1/M4 agonism differs from traditional D2 receptor blockade, summarizes clinical evidence for xanomeline/trospium, and offers practical guidance for patient selection, dosing, tolerability management, monitoring, and counseling.

Released: May 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb. 

Bristol Myers Squibb

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Differentiate dopaminergic and muscarinic mechanisms of actions of novel therapies, and explain the clinical utility to address unmet needs of patients with schizophrenia

  • Evaluate emerging clinical evidence supporting novel therapies in schizophrenia, with attention to efficacy signals, safety considerations, and current limitations of the data

  • Design strategies to integrate novel therapeutic options into treatment plans for patients with schizophrenia while counseling them on optimal administration and side effect management